



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/809,920
Applicant : STENDEL
Filed : March 26, 2004
TC/A.U. : 1614
Examiner :

Docket No. : 1194-280
Customer No. : 06449


INFORMATION DISCLOSURE STATEMENT


Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449. Copies of the US patent documents listed on the accompanying 1449 are not being furnished in accordance with the August 5, 2003 OG notice of waiver of this requirement.

Respectfully submitted,

By 
George R. Repper
Attorney for Applicants
Registration No. 31,414
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 			<i>Complete if Known</i>	
			Application Number	10/809,920
			Filing Date	March 26, 2004
			First Named Inventor	STENDEL
			Group Art Unit	1614
			Examiner Name	
Sheet 1	of 2	Attorney Docket Number	1194-281	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	5,593,665		Pfaffmann et al.	01/14/1997
	2	6,479,481	B1	Stendel et al.	11/12/2002
	3	6,521,616	B2	Calabresi et al.	02/18/2003
	4	5,210,083		Pfaffmann	05/1993


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
	6	WO	01/39763	A2	Rhode Island Hospital, A Lifespan Partner	06/07/2001	
	7	WO	92/00743	A1	Ed Geistlich Sohne fur Chemische Industrie	01/23/1992	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				<i>Complete if Known</i>	
				Application Number	10/809,920
				Filing Date	March 26, 2004
				First Named Inventor	STENDEL
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	1194-281
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	8	BEDROSIAN, I., et al. , "Taurolidine, an Analogue of the Amino Acid Taurine, Suppresses Interleukin 1 and Tumor Necrosis Factor Synthesis in Human Peripheral Blood Mononuclear Cells", <i>Cytokine</i> Vol. 3, No. 6 (November) 1991: 568-575.			
	9	CLARK, K., et al. , "KRN8602 (MX2-hydrochloride): an Active New Agent for the Treatment of Recurrent High-grade Glioma", <i>J. Clin. Oncol.</i> , August 1999, 17 (8): 2579-84, PUBMED Abstract.			
	10	DIMMOCK, Jr, et al. , "Mannich Bases of Phenolic Azobenzenes Possessing Cytotoxic Activity", <i>Eur. J. Med. Chem.</i> (1997) 32, 583-594.			
	11	JACOBI, C.A., et al. , "Intraperitoneal Instillation of Taurolidine and Heparin for the Prevention of Intraperitoneal Tumor Growth and Trocar Metastases in Laparoscopic Surgery in a Rat Model", <i>Lagenbecks Arch Chir</i> (1997) 382 [Suppl. 1]: S31-S36.			AB
	12	JACOBI, C.A., et al. , "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model", <i>Am J of Surgery</i> , Vol. 174, September 1997: 359-363.			
	13	MONSON, J.R.T., et al. , "Taurolidine as an anti-neoplastic agent: a previously undiscovered role?", <i>Br. J. Surg.</i> , Vol. 77, No. 12, December 1990, 1432.			
	14	MONSON, J.R.T., et al. , "Preliminary Evidence that Taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial", <i>Br. J. Surg.</i> , Vol. 77, No. 6, June 1990, A711.			
	15	MONSON, J.R.T., et al. , "Abrogation of tumor necrosis factor (TNF) toxicity in the murine model by taurolidine: support for synergism of TNF with endotoxin", <i>Br. J. Surg.</i> , Vol. 77, No. 6, June 1990, A708.			
	16	MONSON, J.R.T., et al. , "Taurolidine inhibits tumour necrosis factor (TNF) toxicity - new evidence in TNF and endotoxin synergy?", <i>Euro. J. Surg. Oncology</i> , 1993; 19:226-231.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.